The transformation of India’s pharmaceutical industry is a compelling testament to the power of robust intellectual property (IP) laws. The catalyst for this metamorphosis was the amendment of the country’s Patent Act. This shift not only fuelled an expansion of their generics market, but also ignited a flame under their research and development (R&D) prowess. By aligning with global intellectual property standards, Indian pharmaceutical companies pivoted from compliance to competitiveness, becoming major exporters to over 150 countries. With a potent foreign exchange earnings of $19–20 billion, India now plays a central role in the global pharmaceutical market. The refined Patent Law, incorporating Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement flexibilities, has provided Indian firms with the firepower to excel in complex generics, specialties, and innovation across various therapy areas.
This legislative pivot from process patents to product patents ignited a spark that propelled Indian pharmaceutical companies into the global R&D arena. Mumbai-based Sun Pharmaceutical Industries Ltd and Wockhardt Ltd’s recent clinical trial announcements, while intrinsically different, bring to light this shift in focus and capability. While Sun Pharma’s discontinuation of a new drug candidate for severe psoriasis and atopic dermatitis might seem like a setback, it underscores the company’s commitment to rigorous R&D. On the other hand, Wockhardt’s successful trial of Zaynich, a novel antibiotic, showcases the potential of India’s pharmaceutical industry to create globally competitive drugs.
Over the last two decades, the product patent regime has not only revolutionized the drug discovery landscape but also positioned India as a thriving drug manufacturing hub and a promising market for new drugs. This change has also reshaped the dynamics between domestic pharmaceutical firms and their international counterparts, transforming competitive rivals into collaborative partners.
The growth of the domestic pharmaceutical industry during this period is nothing short of phenomenal. In 2005, the Indian drug industry was valued at $8 billion. Fast forward to 2023, and conservative estimates project a value of $50 billion. India’s pharmaceutical industry now ranks as the world’s third-largest by volume and 14th in terms of production value.
However, the industry’s journey hasn’t been without challenges. Ensuring TRIPS compliance, considered the gold standard by the World Trade Organization (WTO), has been a complex task. The Covid-19 pandemic further exposed the structural inequities of the global IP regime, leading India and South Africa to propose a temporary TRIPS waiver in 2020. Despite pressure and delays, the move reaffirmed the importance of flexibility in IP for public health.
The Indian Patent Act’s section 3(d) provision has become a bastion against patent evergreening, while reinforcing the importance of affordability, equity, and health justice in India’s innovation framework. India’s patent law has been instrumental in fostering a robust generics industry that serves not just India, but the world. As we look to the future, these foundational principles will continue to shape the trajectory of India’s pharmaceutical industry. The story of India’s pharmaceutical industry is a powerful reminder of the role that well-crafted legislation can play in driving innovation and growth.
Read more from fortuneindia.com
